Kpg-818    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus2

49. Systemic lupus erythematosus    [ 827 clinical trials,   638 drugs,   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways]
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 827 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04643067
(ClinicalTrials.gov)
December 1, 202012/11/2020A Study to Assess the Safety and Tolerability, PK and Efficacy of KPG-818 in Mild to Moderate SLE PatientsA Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of KPG-818 in Patients With Mild to Moderate Systemic Lupus ErythematosusSLE; DrugDrug: 0.15mg KPG-818 dose;Drug: 0.6mg KPG-818 dose;Drug: 2mg KPG-818 dose;Drug: PlaceboKangpu Biopharmaceuticals, Ltd.NULLNot yet recruiting18 YearsN/AAll64Phase 1;Phase 2NULL
2NCT03949426
(ClinicalTrials.gov)
May 1, 20198/5/2019Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy SubjectsA First-in-Human, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of KPG-818Systemic Lupus ErythematosusDrug: KPG-818Kangpu Biopharmaceuticals, Ltd.NULLCompleted18 Years55 YearsAll40Phase 1United States